Paper20826257
Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
Cadeddu C and 7 others. Am Heart J, 2010. Cited by 108 papers, by iCite.
Cite this record
ConductScience Library. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Papers, record 20826257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20826257
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II Type 1 Receptor Blockers | Major topic |
| Benzimidazoles | Major topic |
| Benzoates | Major topic |
| Heart | Major topic |
| Oxidative Stress | Major topic |
| Adult | |
| Aged | |
| Antibiotics, Antineoplastic | |
| Cytokines | |
| Echocardiography, Doppler | |
| Epirubicin | |
| Female | |
| Humans | |
| Inflammation | |
| Inflammation Mediators | |
| Male | |
| Middle Aged | |
| Myocardial Contraction | |
| Renin-Angiotensin System | |
| Systole | |
| Telmisartan | |
| Ventricular Dysfunction, Left |
Source PubMed
Cited by63
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41595575 | A Narrative Review on Nitrate-Rich Diets as Adjuncts to Antihypertensive Therapy: Enhancing Treatment Efficacy via Oxidative Stress Modulation. | Biomedicines | 2025 | https://conductscience.org/library/papers/41595575 | PubMed |
| 41210341 | Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41210341 | PubMed |
| 41068418 | Effects of renin-angiotensin system inhibitors in cancer patients: a systematic review and meta-analysis of randomized controlled trials. | Hypertens Res | 2025 | https://conductscience.org/library/papers/41068418 | PubMed |
| 40890873 | SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. | Cardiooncology | 2025 | https://conductscience.org/library/papers/40890873 | PubMed |
| 40141815 | Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40141815 | PubMed |
| 39505307 | Cardiovascular Autonomic Dysfunction Before and After Chemotherapy in Cancer Patients. | J Clin Neurol | 2024 | https://conductscience.org/library/papers/39505307 | PubMed |
| 39377963 | Inflammation in Chemotherapy-Induced Cardiotoxicity. | Curr Cardiol Rep | 2024 | https://conductscience.org/library/papers/39377963 | PubMed |
| 39249555 | Cardioprotection strategies for anthracycline cardiotoxicity. | Basic Res Cardiol | 2025 | https://conductscience.org/library/papers/39249555 | PubMed |
| 38348396 | Natural products for the treatment of chemotherapy-related cognitive impairment and prospects of nose-to-brain drug delivery. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38348396 | PubMed |
| 37938165 | Shenmai injection ameliorates doxorubicin-induced myocardial injury by suppressing autophagy-apoptosis via miR-30a. | Aging (Albany NY) | 2023 | https://conductscience.org/library/papers/37938165 | PubMed |
| 37314568 | Comparing Renin-Angiotensin-Aldosterone Blockade Regimens for Long-Term Chemotherapy-Related Cardiac Dysfunction: A Network Meta-Analysis. | Cardiovasc Drugs Ther | 2025 | https://conductscience.org/library/papers/37314568 | PubMed |
| 37257007 | Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity. | Anatol J Cardiol | 2023 | https://conductscience.org/library/papers/37257007 | PubMed |
| 36672461 | Natural Progression of Left Ventricular Function following Anthracyclines without Cardioprotective Therapy: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36672461 | PubMed |
| 36015155 | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36015155 | PubMed |
| 35528842 | Novel Therapeutics for Anthracycline Induced Cardiotoxicity. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35528842 | PubMed |
| 35497981 | Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35497981 | PubMed |
| 34579775 | Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. | Cardiooncology | 2021 | https://conductscience.org/library/papers/34579775 | PubMed |
| 34368589 | Bioactivity Studies of Hesperidin and XAV939. | ACS Omega | 2021 | https://conductscience.org/library/papers/34368589 | PubMed |
| 34356349 | Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34356349 | PubMed |
| 33955207 | Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. | ESC Heart Fail | 2021 | https://conductscience.org/library/papers/33955207 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGTR1 | 185 | PubTator's text mining | https://conductscience.org/library/genes/185 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20826257
GET https://conductscience.org/api/papers/v1/20826257/cited_by?page=2